Similar articles

• Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics.

  Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G. Sabot C, et al. Int J Clin Pharmacol Ther. 1995 Mar;33(3):164-9. Int J Clin Pharmacol Ther. 1995. PMID: 7599915
• Methotrexate pharmacokinetics in patients with rheumatoid arthritis.

  Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino JS Jr. Sinnett MJ, et al. J Rheumatol. 1989 Jun;16(6):745-8. J Rheumatol. 1989. PMID: 2674426
• Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis.

  Chladek J, Grim J, Martinkova J, Simkova M, Vaneckova J. Chladek J, et al. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):247-8. doi: 10.1111/j.1742-7843.2005.pto960318.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733224 Clinical Trial. No abstract available.
• [Amethopterin metabolism in mammalian cells].

  Balińska M. Balińska M. Postepy Biochem. 1988;34(4):417-27. Postepy Biochem. 1988. PMID: 2479942 Review. Polish. No abstract available.
• Methotrexate in dermatology.

  Bangert CA, Costner MI. Bangert CA, et al. Dermatol Ther. 2007 Jul-Aug;20(4):216-28. doi: 10.1111/j.1529-8019.2007.00135.x. Dermatol Ther. 2007. PMID: 17970887 Review.